Merck’s Perlmutter Is Retiring, Handing Over Keytruda To Li
New R&D Head Comes From Discovery And Translation Group
Merck Research Laboratories president Roger Perlmutter returned to the company when its R&D was at a crossroads. Now he is retiring and handing the company’s post-Keytruda growth over to SVP Dean Li.
You may also be interested in...
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Merck Research Laboratories president Dean Li said there is no ideal product mix for the company, but noted cancer drugs will remain a priority given the groundwork Keytruda laid for Merck in oncology.
Eikon launched in 2021 with $148m in series A venture capital and former Merck R&D head Roger Perlmutter as its CEO, but even with half a billion dollars in fresh cash, the firm has not revealed its therapeutic focus.